August 29, 2026
Options imply a 4% move, IV rank is near 79, and call flow is lopsided. Here is what that means for the September 1 release.
Markets don’t need a blowout quarter from Medtronic on Tuesday. They only need the number to land inside a guidance range management has spent three quarters building credibility around. That distinction shapes everything about how to think about MDT’s options into September 1.
Medtronic reports financial results for its first quarter of fiscal year 2027, which ended July 31, 2026, on Tuesday, September 1. The consensus EPS estimate sits at $1.39, which would mark a 10.3% rise compared to the same quarter of the prior year. Revenue consensus is $9.47 billion, a 10.4% increase year-over-year. Management itself guided Q1 EPS to $1.38–$1.40 back in June, so the Street is essentially sitting on top of the midpoint with almost no cushion built in.
The Numbers Behind the Consensus
Full-year FY2027 adjusted EPS guidance is $5.90–$6.00, with first-quarter EPS expected in the $1.38–$1.40 range. Tariffs are modeled at roughly $250 million for the year, with approximately $75 million hitting in Q1, and are projected to reduce FY2027 gross margin by about 20 basis points. That tariff line is the key variable. If Medtronic demonstrates any pass-through or absorption improvement versus its own conservative assumptions, a guide raise becomes the base case rather than upside.
In Q4 FY2026, the company posted adjusted EPS of $1.55, edging past the $1.54 consensus, while revenue climbed 9.9% year-over-year to $9.81 billion, above the $9.62 billion analysts had expected. Organic revenue growth reached 6.6%, with the Cardiovascular segment leading at 13.8%. The question heading into Tuesday is whether that acceleration in the cardiovascular book, driven by pulsed-field ablation and the Affera platform, carries into the fiscal first quarter.
Iran War TRUTH: What Was Revealed Behind Closed Doors
There’s a strategy behind the Iran war.
I know because I heard it directly in a closed-door meeting with a source whose connections run deep into global power networks.
He walked me through the real purpose and the massive deal tied to it.
Needham’s Case and the Product Cycle Argument
Needham raised its price target on MDT to $114 from $101 this week while maintaining a Buy rating; the stock currently trades near $92. Needham cited new product launches, stable market growth, and management’s conservative guidance as factors supporting its expectation of a beat. The firm also expects the company to raise its full-year FY2027 revenue and EPS guidance.
On the product front, the commercial ramp of Affera pulsed-field ablation technology in electrophysiology, continued adoption of the Hugo robotic surgery platform, and integration of recently acquired assets including SPR Therapeutics and Scientia Vascular are the key growth vectors. Peers ISRG and BSX provide context: Intuitive Surgical’s robotic surgery volume growth remains a benchmark for procedural demand, while Boston Scientific’s PFA positioning puts competitive pressure directly on Affera’s ramp rate. MDT’s response to that pressure is what medtech investors are watching most closely on September 1.
Options Market Analysis
Options data compiled by Bloomberg shows MDT shares could move approximately 4% when the company reports earnings on September 1 before the market opens. Implied moves for Medtronic earnings over the past two years have ranged between 3.0% and 4.1%. That is a narrow band for a large-cap medtech, and it sets up an important structural observation: the realized move has frequently exceeded it. The largest actual movement in the past eight quarters was an 8.8% jump in November 2025, more than double the 3.6% implied move at that time.
IV rank for MDT currently reads about 79%, clearing the model floor for premium selling and reading high versus the one-year range. That level reflects earnings-driven demand for options, but the realized volatility picture complicates the pure premium-selling thesis. The 4% expected move on a stock sitting near $91 equates to roughly a $3.60 band in either direction, giving a practical range of approximately $87.40–$94.60 around the event.
Elon Musk Just Called the Dollar “Hopeless” – Then Reinvented It
What’s going on with Elon Musk? Last year, he launched a full-blown attack on the U.S. dollar, calling it “hopeless.” And within months, he hatched a plan to reinvent the world reserve currency. Now, with the blessing of President Trump and the U.S. Treasury, it’s coming to life. And investors who grasp what’s going on could make a fortune.
The call/put ratio in MDT options stands above 10 calls for every put, signaling traders are positioning for an upside move, potentially on earnings. The $100 September 2026 call saw 18,801 contracts traded against open interest of only 1,704, representing a wave of fresh bullish positioning rather than rolled existing exposure. That asymmetry is worth respecting even for traders who disagree with the directional view.
Structured Trade Framework
Bull case: For traders expecting a beat and a guidance raise, a defined-risk structure would be a September call vertical, buying the $92 call and selling the $97 call. The spread captures an upside move toward the 52-week midpoint while capping premium outlay against a stock that has already run 10% over the past month.
Bear case: MDT trades at a forward P/E of roughly 15.5x. If guidance disappoints again as it did in June when full-year EPS came in below the Street’s $6.06 estimate, the discount does not provide much floor. A defined-risk bear structure would be a September put vertical, buying the $90 put and selling the $85 put, sized to risk no more than 1% of portfolio capital.
The Small Rocket Company Trading for Pennies on the Dollar (Compared to the Big Names)
Did you know there’s public space company, with incredible potential? And it’s probably not the one you are thinking of.
Neutral case: Given a 4% expected move, an IV rank near 80, and a stock that moved less than 1% after the Q4 beat in June, a short iron condor centered on $91 with wings at $85 and $97 collects premium while staying inside the realized-move distribution of the past two quarters. This is the structure that fits a low-volatility release scenario most cleanly.
Risk and Forward Outlook
Macroeconomic risks, including tariff escalations and foreign-exchange headwinds given Medtronic’s substantial international revenue, warrant attention alongside evolving reimbursement policies in major markets. Insider selling remains a disclosed overhang. The MiniMed diabetes unit separation remains a multi-step process, and that timeline can introduce additional forecast uncertainty that management has conservatively embedded into its guidance but the market has not fully priced.
This is not about whether Medtronic is a good business. It is about whether a $91 stock with a 4% implied move, about 79 IV rank, and a 10-to-1 call skew is offering premium sellers a fair price. The answer is: barely, and only with defined risk on both sides. Tuesday will clarify quickly.
Action Checklist
- Verify consensus EPS ($1.39) and revenue ($9.47B) at open Tuesday; any Q1 beat above $1.41 and revenue above $9.55B increases guide-raise probability.
- Watch Q1 tariff commentary: $75M headwind is already in estimates; any improvement signals FY2027 upside.
- Monitor Cardiovascular segment organic growth rate against the 13.8% Q4 pace; deceleration below 10% would pressure the stock despite a headline EPS beat.
- Track IV crush post-earnings: expect MDT IV to drop 8–12 points after the release regardless of direction.
- For a neutral defined-risk structure, close the iron condor if MDT moves more than 3.5% in either direction by midday September 1.
- Needham’s $114 target and the 10-to-1 call skew are directional signals, not guarantees. Size positions to survive a repeat of the February 17, 2026 outcome, when MDT fell 5.2% despite the implied move being only 3.6%.
